This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2002 Dec;156(12):1180-1.

doi: 10.1001/archpedi.156.12.1180.

Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?

Terry P Klassen

PMID: 12444825
DOI: 10.1001/archpedi.156.12.1180

Editorial

Economic evaluations of immunoprophylaxis in infants at high risk for respiratory syncytial virus: shedding light or creating confusion?

Terry P Klassen. Arch Pediatr Adolesc Med. 2002 Dec.

. 2002 Dec;156(12):1180-1.

doi: 10.1001/archpedi.156.12.1180.

Author

Terry P Klassen

PMID: 12444825
DOI: 10.1001/archpedi.156.12.1180

No abstract available

PubMed Disclaimer

Comment on

Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review.
Kamal-Bahl S, Doshi J, Campbell J. Kamal-Bahl S, et al. Arch Pediatr Adolesc Med. 2002 Oct;156(10):1034-41. doi: 10.1001/archpedi.156.10.1034. Arch Pediatr Adolesc Med. 2002. PMID: 12361451

Similar articles

Revised indications for the use of palivizumab and respiratory syncytial virus immune globulin intravenous for the prevention of respiratory syncytial virus infections.
Meissner HC, Long SS; American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Meissner HC, et al. Pediatrics. 2003 Dec;112(6 Pt 1):1447-52. doi: 10.1542/peds.112.6.1447. Pediatrics. 2003. PMID: 14654628
RSV immune globulin prophylaxis: is an ounce of prevention worth a pound of cure?
Moler FW. Moler FW. Pediatrics. 1999 Sep;104(3 Pt 1):559-60. doi: 10.1542/peds.104.3.559. Pediatrics. 1999. PMID: 10469785 No abstract available.
Humanized monoclonal antibody for prevention of respiratory syncytial virus infection.
Storch GA. Storch GA. Pediatrics. 1998 Sep;102(3 Pt 1):648-51. doi: 10.1542/peds.102.3.648. Pediatrics. 1998. PMID: 9738192 No abstract available.
Immunoprophylaxis for respiratory syncytial virus.
Sánchez PJ. Sánchez PJ. Pediatr Infect Dis J. 2002 May;21(5):473-8. doi: 10.1097/00006454-200205000-00036. Pediatr Infect Dis J. 2002. PMID: 12150195 Review. No abstract available.
Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion.
Meissner HC, Welliver RC, Chartrand SA, Law BJ, Weisman LE, Dorkin HL, Rodriguez WJ. Meissner HC, et al. Pediatr Infect Dis J. 1999 Mar;18(3):223-31. doi: 10.1097/00006454-199903000-00004. Pediatr Infect Dis J. 1999. PMID: 10093942 Review. No abstract available.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Medical
- MedlinePlus Health Information